| Biaxin xl 500mg clarithromycin
Rapidly absorbed from the gastrointestinal tract after oral administration.
The absolute bioavailability of approximately 50%. Repeated dose reception cumulation is not found in nature and metabolism in the human body has not changed. Eating just prior to drug intake increases the bioavailability of the drug by an average of 25%. Clarithromycin may be used before meals or during meals. Communication with plasma proteins - more than 90%. After a single dose of 2 recorded maximum peak concentration. The second peak is due to the ability of the drug to concentrate in the gall bladder, followed by gradual or fast entering the intestine and absorption. Time to maximum concentration after oral administration of 250 g m - 3.1 hours.
Biaxin xl 500mg clarithromycin
After oral administration, 20% of the dose rapidly hydroxylated in the liver enzyme cytochrome CYP3A4, CYP3A5, CYP3A7 with the formation of the major metabolite - 14 hydroxyclarithromycin having pronounced antimicrobial activity against Haemophilus influenzae. With regular use of 250 mg / day, the concentration of the unchanged drug and its major metabolite - 1 and 0.6 ug / ml, respectively; half-life - 3-4 and 5-6 hours, respectively. When increasing the dose to 500 mg / day, the concentration of unchanged drug and its metabolite in plasma - 0,83-0,88 and 2.7-2.9 ug / ml, respectively; half-life - and 4,8-5 6,9-8,7 hours, respectively. At therapeutic concentrations accumulate in the lungs, skin and soft tissues (which is 10 times higher than a serum level concentration).
Excreted by the kidneys and through the gastrointestinal tract (GIT) (20-30% - in unmodified form, the rest - in the form of metabolites). In single dose of 250 mg and 1200 allocated 37.9 kidneys and 46% through the gastrointestinal tract, 40.2 and 29.1%, respectively.
Biaxin xl 500mg clarithromycin
Infectious-inflammatory diseases caused by susceptible to malaria infections;
Infections of the upper respiratory tract; LOP tract infection (pharyngitis, sinusitis);
Infections of the lower respiratory tract (pneumonia, bronchitis);
Infections of skin and soft tissue (folliculitis, cellulitis, erysipelas);
Odontogenic infections;
Mycobacterial infections caused by Mycobacterium avium, Mycobacterium intracellular localized infection caused by Mycobacterium kansasii, Mycobacterium chelonae, Mycobacterium fortuitum.
Preventing the spread of infection caused by Mycobacterium complex avium (MAC), HIV-infected patients with the content of lymphocytes CD 4 (T-helper lymphocytes) is not more than 100 in 1 mm3.
For Helicobacter pylori eradication and the reduction of recurrence of duodenal ulcer.
|